Some sparse scientific data support the hypothesis that otherwise unexplained emphysema may be associated with FLNA variants. This transversal multicentric study aimed to describe the frequency of emphysema in patients carrying an FLNA variation. Patients with FLNA variations who accept the study will benefit from a chest physician's clinical examination, respiratory function tests, a cardiac ultrasound and a chest scan. The primary endpoint is to describe emphysema's frequency in patients carrying FLNA variation. The other objectives are to describe emphysema's features in these patients, the prevalence of pulmonary hypertension and to describe their lung function abnormalities. The final goal is to confirm the association between unexplained emphysema and FLNA mutation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
70
1. Radiation: Chest HRCT A chest HRCT to identify emphysema 2. Genetic: blood analysis If emphysema is identified, a blood analysis will be performed to exclude known causes of emphysema (Alpha-1 antitrypsin deficiency) NTproBNP for all patients 3. Lung function tests Lung function tests will be performed in accordance with ATS/ERS technical standard 4. Cardiac ultrasound
Lille University Hospital
Lille, France
Frequency of emphysema in patients carrying FLNA mutation
Presence of emphysema on chest CT scans, defined as the presence of focal areas or regions of low attenuation, generally without visible walls: qualitative and quantitative analysis through visual and automated computer quantification of the number of voxels with a density below -950 HU (centralized review of CT scans)
Time frame: 6 months +/- 2 weeks
Morphological of emphysema
\- type of emphysema: centrilobular/panlobular/mixed
Time frame: 6 months +/- 2 weeks
Topographical characteristics of emphysema
predominant distribution of emphysema: upper regions/lower regions/no predominant distribution
Time frame: 6 months +/- 2 weeks
Severity of emphysema
objective quantification of emphysema: % of lung volume occupied by emphysema (% of lung with density\<-950 HU, 15th percentile parenchyamal density); use of quantification software, available in clinical routine (eXamine; Siemens Healthineers)
Time frame: 6 months +/- 2 weeks
Probabilistic diagnosis of pulmonary hypertension
Probabilistic diagnosis of pulmonary hypertension by echocardiography according to ERS/ESC guidelines, based on measurement of the maximum tricuspid regurgitation velocity in m/s and the presence of indirect signs suggestive of pulmonary hypertension as defined by ERS/ESC guidelines.
Time frame: 6 months +/- 2 weeks
Prevalence of pulmonary hypertension
Time frame: 6 months +/- 2 weeks
Descriptive analysis of functional respiratory abnormalities measured by the functional respiratory test
Percentage of patients with obstructive ventilatory dysfunction defined by a post-bronchodilator FEV1/FVC ratio \<LLN " (LLN = lower limit of normal
Time frame: 6 months +/- 2 weeks
Frequency of unexplained emphysema in patients carrying a FLNA mutation
Time frame: 6 months +/- 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.